Evidence Hub

In vitro antimicrobial susceptibility of Mycoplasma pneumoniae isolates across different regions of China in 2023

Yan C, Chen Y, Ren X, Jia X, Du B, Zhao H, Feng Y, Xue G et al.

JAC-antimicrobial resistance, 2025

2 citations

Abstract

Abstract Objectives To analyse the in vitro antimicrobial susceptibility of Mycoplasma pneumoniae (M. pneumoniae) isolates from 10 different provinces/municipalities across China during the 2023 epidemic. Methods We collected respiratory specimens from paediatric patients diagnosed with M. pneumoniae pneumonia from 10 different provinces/municipalities including Beijing, Shanghai, Liaoning, Gansu, Shanxi, Henan, Hunan, Jiangsu, Guangxi and Guangdong across China from October to December 2023. M. pneumoniae was isolated and cultured from these specimens. Macrolide resistance-associated mutations A2063G or A2064G in the 23S rRNA gene were detected. Minimum inhibitory concentrations (MICs) of five antibiotics (erythromycin, azithromycin, tetracycline, moxifloxacin and doxycycline) were determined using PPLO broth and microdilution susceptibility tests. Results A total of 190 M. pneumoniae isolates were analysed. All isolates harboured the A2063G mutation. All isolates (100%) were highly resistant to erythromycin (MIC range: 128–1024 mg/L) and azithromycin (MIC range: 4–256 mg/L), but susceptible to tetracycline (MIC range: ≤0.125–1 mg/L), doxycycline (MIC range: ≤0.125–1 mg/L) and moxifloxacin (MIC range: ≤0.125 mg/L). For azithromycin and tetracycline, M. pneumoniae isolates from different regions of China showed different susceptibilities. The MICs of tetracycline against M. pneumoniae from northern China were significantly lower than those from central China and southern…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free